Abstract: Disclosed herein is a method of detecting and identifying antigens that are shed into human bodily fluids during infection. The disclosed method allows circulating antigens associated with a particular infection to be detected within minutes or hours from testing as compared to days required with the current methods. Methods of identifying diagnostic indicators/targets for a given condition or disease are disclosed which include immunizing a veterinary subject with biological fluids obtained from a human infected with particular antigens to identify diagnostic targets for immunoassay. Also disclosed are methods of diagnosing and monitoring a B. burgdorferi-associated condition, such as Lyme disease. Point-of-care immunoassays are also provided that can be used to diagnose or monitor the efficacy of a B. burgdorferi-associated condition treatment. These immunoassays can also be used for rapid diagnosis of infection produced by B. burgdorferi, such as Lyme disease.

Abstract: This disclosure relates to systems and methods for educating and empowering patients and their caregivers. In one aspect, a system for providing medical information to a user includes a healthcare provider terminal, a patient record database, a patient-diagnostic processor, and an interface. The healthcare provider terminal may enable uploading of a plurality of laboratory test results, wherein each laboratory test result measures a quantity of each of a respective plurality of substances in a patient. The patient record database may include historical laboratory test results associated with the patient. The patient-diagnostic processor may generate a plurality of informational displays based on the patient's plurality of laboratory test results and the patient's historical laboratory test results, wherein each informational display provides a visualization of a change in the quantity of the respective substance over a period of time. The interface may display the plurality of displays.

Abstract: This disclosure relates to systems and methods for educating and empowering patients and their caregivers. In one aspect, a system for providing medical information to a user includes a healthcare provider terminal, a patient record database, a patient-diagnostic processor, and an interface. The healthcare provider terminal may enable uploading of a plurality of laboratory test results, wherein each laboratory test result measures a quantity of each of a respective plurality of substances in a patient. The patient record database may include historical laboratory test results associated with the patient. The patient-diagnostic processor may generate a plurality of informational displays based on the patient's plurality of laboratory test results and the patient's historical laboratory test results, wherein each informational display provides a visualization of a change in the quantity of the respective substance over a period of time. The interface may display the plurality of displays.

Abstract: Non-invasive methods are provided herein for the diagnosis of melioidosis with specific antibodies capable of detecting molecules associated with melioidosis in a biological fluid, such as urine or serum. These molecules can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay. Methods of inducing an immune response to melioidosis are also disclosed. The methods include the use of the immunogenic melioidosis polypeptides, nucleic acids encoding these polypeptides, and/or viral vectors encoding an immunogenic melioidosis polypeptide, alone or in conjunction with other agents, such as traditional melioidosis therapies. Also disclosed are methods for treating a subject having melioidosis.

Abstract: Disclosed herein are methods of diagnosing, monitoring and treating an Aspergillus species-associated condition, such as Aspergillus fumigatus (Af)-associated condition, including aspergillosis, such as invasive aspergillosis (IA). Methods for diagnosing and/or monitoring an Aspergillus species-associated condition, such as IA are provided. Also disclosed are point-of-care immunoassays that can be used to diagnose or monitor the efficacy of an Aspergillus-associated condition treatment. These immunoassays can also be used for rapid diagnosis of infection produced by an Aspergillus species, such as Af.

Abstract: Non-invasive methods are provided herein for the diagnosis of melioidosis with specific antibodies capable of detecting molecules associated with melioidosis in a biological fluid, such as urine or serum. These molecules can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay. Methods of inducing an immune response to melioidosis are also disclosed. The methods include the use of the immunogenic melioidosis polypeptides, nucleic acids encoding these polypeptides, and/or viral vectors encoding an immunogenic melioidosis polypeptide, alone or in conjunction with other agents, such as traditional melioidosis therapies. Also disclosed are methods for treating a subject having melioidosis.